Exclusive Summary

• **Addressing Massive Unmet Need**: Targets Traumatic Brain Injury (TBI), a global indication with 50-69 million annual cases, filling the gap for effective neuro-restorative therapies.
• **First-in-Class Innovation**: Utilizes specific stress-adaptive protein therapy via the ECIWEP platform, offering a 'multi-target neural network repair' mechanism that shifts the paradigm from single-factor repair to systemic reconstruction.
• **Superior CMC & Safety Profile**: A 'cell-free' and 'non-exosomal' biologic that eliminates the safety risks (tumorigenicity) and manufacturing inconsistencies of stem cell therapies, ensuring high purity and scalability.
• **De-risked by Cross-Indication Validation**: The core molecule (UBD001) has demonstrated efficacy in ALS (FDA Orphan Drug Designation) and Stroke, validating the neuro-repair mechanism and significantly reducing development risks for TBI.

Asset Materials

Contact Us for Full Materials